General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Blackbird on Sale of its Stake in Cygna Labs

September 11, 2020
Cross-border team represents US venture capital investor in sale of its remaining stake in provider of compliance software solutions.

Latham & Watkins LLP has advised US venture capital investor Blackbird Ventures (Blackbird) on the sale of its remaing stake in Cygna Labs, a leading provider of compliance software solutions, to n3k Informatik (n3k), a VR Equitypartner portfolio company. Latham had already advised Blackbird in 2018 on the sale of its majority stake in Cygna Labs to n3k. Financial details remain confidential.

Blackbird incubates, and invests in, early-stage technology companies, providing operational support along the entire startup trajectory to develop market-transforming businesses.

Latham & Watkins LLP represented Blackbird with a corporate team led by Hamburg partner Stefan Widder, with Washington, D.C. counsel Joseph Simei, and Hamburg associates Jacob Ahme and Maximilian Berenbrok.